JPWO2021076444A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021076444A5
JPWO2021076444A5 JP2022522322A JP2022522322A JPWO2021076444A5 JP WO2021076444 A5 JPWO2021076444 A5 JP WO2021076444A5 JP 2022522322 A JP2022522322 A JP 2022522322A JP 2022522322 A JP2022522322 A JP 2022522322A JP WO2021076444 A5 JPWO2021076444 A5 JP WO2021076444A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
breast cancer
composition
composition according
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522322A
Other languages
Japanese (ja)
Other versions
JP2022551672A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055219 external-priority patent/WO2021076444A1/en
Publication of JP2022551672A publication Critical patent/JP2022551672A/en
Publication of JPWO2021076444A5 publication Critical patent/JPWO2021076444A5/ja
Pending legal-status Critical Current

Links

Claims (7)

有効量のダパンストリルまたは医薬として許容される量の溶媒和物を含む、対象における乳癌の治療に使用するための医薬組成物。 A pharmaceutical composition for use in treating breast cancer in a subject , comprising an effective amount of dapanstril or a pharmaceutically acceptable amount of a solvate. 前記乳癌が非浸潤性乳管癌（ＤＣＩＳ）、浸潤性乳管癌（ＩＤＣ）、トリプルネガティブ乳癌（ＴＮＢＣ）、炎症性乳癌(ＩＢＣ)、転移性乳癌、および妊娠中の乳癌からなる群から選択される、請求項1に記載の医薬組成物。 The breast cancer is selected from the group consisting of ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer (IBC), metastatic breast cancer, and breast cancer during pregnancy. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is 前記組成物が経口組成物である、請求項１に記載の医薬組成物。 A pharmaceutical composition according to claim 1, wherein said composition is an oral composition. 前記組成物が乳腺腫瘍の大きさを減少させる、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein the composition reduces the size of mammary tumors. 前記組成物が乳腺腫瘍のさらなる成長を減少させる、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein the composition reduces further growth of mammary tumors. 前記組成物が有効量のチェックポイント阻害剤とともに使用される、請求項１に記載の医薬組成物。 2. A pharmaceutical composition according to claim 1, wherein said composition is used in conjunction with an effective amount of a checkpoint inhibitor . 前記チェックポイント阻害剤が抗ＰＤ－１抗体である、請求項６に記載の医薬組成物。 7. The pharmaceutical composition according to claim 6, wherein the checkpoint inhibitor is an anti-PD-1 antibody.
JP2022522322A 2019-10-14 2020-10-12 breast cancer treatment Pending JP2022551672A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914833P 2019-10-14 2019-10-14
US62/914,833 2019-10-14
PCT/US2020/055219 WO2021076444A1 (en) 2019-10-14 2020-10-12 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
JP2022551672A JP2022551672A (en) 2022-12-12
JPWO2021076444A5 true JPWO2021076444A5 (en) 2023-09-20

Family

ID=75538857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522322A Pending JP2022551672A (en) 2019-10-14 2020-10-12 breast cancer treatment

Country Status (6)

Country Link
US (1) US20220249425A1 (en)
EP (1) EP4045009A4 (en)
JP (1) JP2022551672A (en)
CN (1) CN114555053A (en)
AU (1) AU2020366300A1 (en)
WO (1) WO2021076444A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
CN110167538B (en) * 2017-01-06 2022-11-29 欧拉泰克治疗有限责任公司 Methods for treating cardiovascular disease
CN111670032A (en) * 2018-01-31 2020-09-15 欧拉泰克治疗有限责任公司 Methods for preventing or treating alzheimer's disease
CN111867678B (en) * 2018-03-21 2023-04-28 欧拉泰克治疗有限责任公司 Method for treating melanoma

Similar Documents

Publication Publication Date Title
Catania et al. Mondor's disease and breast cancer
McCormack et al. The changing role of surgery for pulmonary metastases
Fu et al. Non‐epithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx: A clinicopathologic study. I General Features and Vascular Tumors
STOUT Superficial spreading type of carcinoma of the stomach
Young et al. Atypical forms of microglandular hyperplasia of the cervix simulating carcinoma: a report of five cases and review of the literature
Arguelles et al. Necrotizing sialometaplasia
JP2020511467A5 (en)
Shrivastava et al. Management of vaginal cancer
JP2005526064A5 (en)
Madden Jr et al. Multiple biliary papillomatosis
Kayikçioğlu et al. Inflammatory breast metastases of ovarian cancer: a case report
JPWO2021076444A5 (en)
Govan et al. Aberrant glandular polypi of the uterine cervix associated with contraceptive pills: pathology and pathogenesis
Butler et al. Primary invasive breast carcinoma arising in mammary-like glands of the vulva managed with excision and sentinel lymph node biopsy
Amagasa et al. A study of the clinical characteristics and treatment of oral carcinoma in situ
WELBORN et al. Lymphoma of the stomach: A diagnostic and therapeutic problem
Froio et al. Lymphangiosarcoma in post-mastectomy lymphedema
Hørding et al. Stage I endometrial carcinoma: a review of 140 patients primarily treated by surgery only
JPWO2021087136A5 (en)
McMillan et al. Bilateral mandibular metastases
RU2016133285A (en) PHARMACEUTICAL COMBINATIONS
Taylor et al. A new method for visualization of the gastric wall: a preliminary report
JPWO2019182981A5 (en)
Wolcott et al. Mesotheliomas of the pleura
Helmi et al. Bartholin gland carcinoma: A case report